Jump to: About ICER | Get Involved
The Institute for Clinical and Economic Review
Who decides which medications are available to the 102 million Americans fighting high cholesterol?
Increasingly, questions of access are informed by the Institute for Clinical and Economic Review, or ICER. The health economics organization uses clinical trials data and available pricing information to consider whether a drug is worth its cost.
Now ICER is reviewing new treatments for high LDL, or “bad,” cholesterol. ICER’s upcoming review will examine three medications that treat a form of inherited high cholesterol, called heterozygous familial hypercholesterolemia, as well as secondary prevention of ASCVD:
Inclisiran, a twice-yearly injected PCSK9 inhibitor
Bempedoic acid, an adjunct therapy for statin treatment
Bempedoic acid/ezetimibe, an adjunct therapy for statin treatment with added ability to lower lipids.
Get Involved
ICER’s reports can influence health plans’ decisions about coverage. Input from advocacy organizations, health care providers and patients is critical.
Social Media Graphics
Raise awareness about the importance of treatment options for high cholesterol.
Who Needs Options for Treating High Cholesterol?
Why Patient-Centered Care is Important for High Cholesterol
To download and share: Click an image above, then right click and choose "save image as". Choose a destination on your computer, such as your desktop or a folder, and click save. Then, post to Facebook or Twitter just as you would any other image.
How ICER Underestimates High Cholesterol
ICER claims that new medications for high cholesterol aren’t worth their cost. The economists overlook the needs of high-risk patients – and underestimate the impact of high cholesterol.
Heart Doctors Want ICER to Get Real
By Dharmesh Patel, MD
“Waiting is a dangerous game for high-risk cardiovascular patients. So I urge ICER to take into consideration the input of physicians, along with other advocates, as their economists update the evidence report. Patients with an all-too-real risk of cardiovascular events are depending upon it.”